AxoGen (NASDAQ:AXGN - Get Free Report) is expected to be releasing its Q3 2025 results before the market opens on Wednesday, October 29th. Analysts expect AxoGen to post earnings of $0.09 per share and revenue of $56.8990 million for the quarter. Interested persons are encouraged to explore the company's upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Wednesday, October 29, 2025 at 8:00 AM ET.
AxoGen Stock Up 3.1%
AXGN stock opened at $17.49 on Wednesday. The company has a current ratio of 4.14, a quick ratio of 2.67 and a debt-to-equity ratio of 0.59. AxoGen has a twelve month low of $9.22 and a twelve month high of $21.00. The company's 50 day moving average is $16.43 and its two-hundred day moving average is $14.03. The stock has a market cap of $804.77 million, a P/E ratio of -174.88 and a beta of 1.04.
Analysts Set New Price Targets
A number of analysts have weighed in on AXGN shares. HC Wainwright started coverage on shares of AxoGen in a report on Tuesday, September 30th. They set a "buy" rating and a $25.00 price objective on the stock. Wall Street Zen raised shares of AxoGen from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of AxoGen in a report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $25.75.
Check Out Our Latest Stock Report on AXGN
Insider Activity at AxoGen
In other news, Director William P. Mr. Burke sold 14,571 shares of AxoGen stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $18.21, for a total value of $265,337.91. Following the transaction, the director directly owned 2,293 shares of the company's stock, valued at $41,755.53. The trade was a 86.40% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Over the last 90 days, insiders have sold 34,064 shares of company stock valued at $615,964. Insiders own 2.78% of the company's stock.
Hedge Funds Weigh In On AxoGen
Several institutional investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC boosted its position in shares of AxoGen by 189.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,079 shares of the medical equipment provider's stock worth $55,000 after purchasing an additional 3,327 shares in the last quarter. State of Wyoming purchased a new stake in shares of AxoGen during the 2nd quarter worth $69,000. The Manufacturers Life Insurance Company boosted its position in shares of AxoGen by 7.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 16,194 shares of the medical equipment provider's stock worth $176,000 after purchasing an additional 1,079 shares in the last quarter. Jones Financial Companies Lllp boosted its position in shares of AxoGen by 104,810.0% during the 1st quarter. Jones Financial Companies Lllp now owns 10,491 shares of the medical equipment provider's stock worth $194,000 after purchasing an additional 10,481 shares in the last quarter. Finally, AQR Capital Management LLC boosted its position in shares of AxoGen by 45.3% during the 1st quarter. AQR Capital Management LLC now owns 23,917 shares of the medical equipment provider's stock worth $442,000 after purchasing an additional 7,453 shares in the last quarter. 80.29% of the stock is owned by institutional investors and hedge funds.
About AxoGen
(
Get Free Report)
AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AxoGen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AxoGen wasn't on the list.
While AxoGen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
